Zevra Therapeutics Inc. (NASDAQ:ZVRA) — Market Cap & Net Worth
Market Cap & Net Worth: Zevra Therapeutics Inc. (ZVRA)
Zevra Therapeutics Inc. (NASDAQ:ZVRA) has a market capitalization of $516.25 Million ($516.25 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12376 globally and #2901 in its home market, demonstrating a -0.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zevra Therapeutics Inc.'s stock price $10.07 by its total outstanding shares 56297535 (56.30 Million). Analyse Zevra Therapeutics Inc. cash flow conversion to see how efficiently the company converts income to cash.
Zevra Therapeutics Inc. Market Cap History: 2015 to 2026
Zevra Therapeutics Inc.'s market capitalization history from 2015 to 2026. Data shows change from $17.89 Billion to $566.92 Million (-26.65% CAGR).
Index Memberships
Zevra Therapeutics Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #317 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1178 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.03% | #180 of 263 |
Weight: Zevra Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zevra Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zevra Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19.88x
Zevra Therapeutics Inc.'s market cap is 19.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $341.39 Million | $12.84 Million | -$24.52 Million | 26.59x | N/A |
| 2020 | $630.53 Million | $13.29 Million | -$12.76 Million | 47.45x | N/A |
| 2021 | $490.35 Million | $28.65 Million | -$8.55 Million | 17.12x | N/A |
| 2022 | $258.41 Million | $10.16 Million | -$26.77 Million | 25.43x | N/A |
| 2023 | $368.75 Million | $27.46 Million | -$46.05 Million | 13.43x | N/A |
| 2024 | $469.52 Million | $23.61 Million | -$105.51 Million | 19.88x | N/A |
Competitor Companies of ZVRA by Market Capitalization
Companies near Zevra Therapeutics Inc. in the global market cap rankings as of May 2, 2026.
Key companies related to Zevra Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Zevra Therapeutics Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Zevra Therapeutics Inc.'s market cap moved from $17.89 Billion to $ 566.92 Million, with a yearly change of -26.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $566.92 Million | +12.39% |
| 2025 | $504.43 Million | +7.43% |
| 2024 | $469.52 Million | +27.33% |
| 2023 | $368.75 Million | +42.70% |
| 2022 | $258.41 Million | -47.30% |
| 2021 | $490.35 Million | -22.23% |
| 2020 | $630.53 Million | +84.70% |
| 2019 | $341.39 Million | -78.71% |
| 2018 | $1.60 Billion | -56.05% |
| 2017 | $3.65 Billion | +37.29% |
| 2016 | $2.66 Billion | -85.15% |
| 2015 | $17.89 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Zevra Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $516.25 Million USD |
| MoneyControl | $516.25 Million USD |
| MarketWatch | $516.25 Million USD |
| marketcap.company | $516.25 Million USD |
| Reuters | $516.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more